Levron Cardiovascular

Company Overview

Snapshot

Founded in June 2021 by Meir Kenigsztein, Dr. Shimon Eckhouse, and Prof. Amir Landesberg, Levron Cardiovascular operates with 1–10 employees. The company has secured funding across one disclosed round from four investors. In November 2025, Levron Medical exited stealth mode, establishing a new category of heart failure treatment through its CRPA technology.

Business overview

Levron Cardiovascular is a Health Tech & Life Sciences company focused on developing a novel autonomic integrated diagnostic and therapeutic minimally invasive device for cardiac failure patients. The company's technology integrates diagnosis and treatment to shift fluids from the lung and reduce cardiac workloads, providing adaptive treatment for NYHA stage 3 heart failure and eliminating lung congestion. Levron operates within the medical devices, cardiology, and therapeutic devices sectors, targeting patients with heart failure.

Strategic signal

In November 2025, Levron Medical exited stealth mode to introduce a new category of heart failure treatment utilizing its CRPA technology. This move signals a significant advancement in the company's product development and market strategy, indicating a readiness to commercialize its innovative minimally invasive device. For investors, this suggests a transition from R&D to market validation, potentially accelerating future growth and adoption within the cardiology and medical device industries.

Company Intelligence Q&A

When was Levron Cardiovascular founded?

Levron Cardiovascular was founded in June 2021.

Who are the co-founders of Levron Cardiovascular?

Levron Cardiovascular was co-founded by Meir Kenigsztein, Dr. Shimon Eckhouse, and Prof. Amir Landesberg.

What is Levron Cardiovascular's primary focus?

Levron Cardiovascular develops a novel autonomic integrated diagnostic and therapeutic minimally invasive device for patients with cardiac failure, aiming to treat NYHA stage 3 heart failure.

What significant corporate milestone did Levron Medical achieve recently?

In November 2025, Levron Medical exited stealth mode to establish a new category of heart failure treatment using its CRPA technology.

Which investors participated in Levron Cardiovascular's funding round?

Levron Cardiovascular secured funding in November 2025 from investors including Shoni Health Ventures.